Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2023-06-23 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended April 30, 2023 and 2022' and is unaudited. It contains detailed financial statements including statements of financial position, loss and comprehensive loss, cash flows, and changes in shareholders' equity for interim periods (three and nine months). The document references compliance with National Instrument 51-102 and IFRS, and includes notes to the financial statements. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly identify this as an Interim / Quarterly Report containing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2023-06-23 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the completion of preclinical toxicology studies (dog and rat GLP studies) for a drug candidate, Marvel Biosciences Corp.'s MB-204, which is a step before entering human trials. It discusses study progress, expected timelines for data, and the company's drug development approach. There are no financial statements, regulatory filings, voting results, or management changes. The content is an update on research and development progress, typical of a capital/financing update or clinical trial progress announcement. However, it does not discuss fundraising, capital structure changes, or financing activities explicitly. It is not a regulatory filing or earnings release. Given the nature of the announcement as a progress update on drug development milestones, the best fitting category is Capital/Financing Update (CAP), as it relates to the company's advancement towards clinical trials which is material to investors and capital markets.
2023-04-20 English
Interim MD&A - English.pdf
Regulatory Filings
2023-03-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2023. It is a certification letter rather than the interim report itself. The document length is 3066 characters, which is relatively short and contains no actual financial data or substantive financial analysis. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2023-03-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2023. It is a certification letter rather than the interim report itself. The document is short (3043 characters) and primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR).
2023-03-31 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.